<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327518</url>
  </required_header>
  <id_info>
    <org_study_id>NXGT-202-QROS</org_study_id>
    <nct_id>NCT04327518</nct_id>
  </id_info>
  <brief_title>Evaluation of the Rotational Stability of the Tecnis Toric II IOL</brief_title>
  <acronym>STEELE</acronym>
  <official_title>Clinical Investigation of Rotational Stability of the TECNIS® Toric II Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Surgical Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Surgical Vision, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, single-arm, open-label clinical study of the commercially&#xD;
      available TECNIS Toric II IOL. The study will be conducted in up to 192 subjects needing&#xD;
      unilateral or bilateral cataract surgery in up to 8 sites in United States (US). The subjects&#xD;
      will be followed for up to 3-months postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of eyes with ≤ 5º axis misalignment from the intended IOL axis of orientation</measure>
    <time_frame>1 week Postoperative</time_frame>
    <description>Rotational stability of the IOL will be evaluated by measuring axis misalignment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Cataract</condition>
  <condition>Corneal Astigmatism</condition>
  <arm_group>
    <arm_group_label>TECNIS® Toric II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be implanted in one or both eyes with the study lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TECNIS® Toric II</intervention_name>
    <description>Toric Intraocular Lens</description>
    <arm_group_label>TECNIS® Toric II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Minimum 22 years of age;&#xD;
&#xD;
          2. Unilateral or Bilateral cataracts for which cataract extraction and posterior chamber&#xD;
             IOL implantation have been planned;&#xD;
&#xD;
          3. Pre-existing corneal astigmatism of one diopter or greater;&#xD;
&#xD;
          4. Predicted residual refractive cylinder based on toric IOL calculator, considering&#xD;
             surgically induced astigmatism (SIA) and posterior corneal astigmatism (PCA) must be&#xD;
             ≤0.50 D;&#xD;
&#xD;
          5. Potential for postoperative BCDVA of 20/30 Snellen or better;&#xD;
&#xD;
          6. Clear intraocular media other than cataract in each eye;&#xD;
&#xD;
          7. Availability, willingness and sufficient cognitive awareness to comply with&#xD;
             examination procedures and study visits;&#xD;
&#xD;
          8. Signed informed consent form (ICF) and health insurance portability and accountability&#xD;
             act (HIPAA) authorization;&#xD;
&#xD;
          9. Ability to understand and respond to a questionnaire in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Irregular corneal astigmatism;&#xD;
&#xD;
          2. Any corneal pathology/abnormality other than regular corneal astigmatism or corneal&#xD;
             instability due to contact lens wear;&#xD;
&#xD;
          3. Previous corneal or intraocular surgery;&#xD;
&#xD;
          4. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus,&#xD;
             nystagmus, etc.);&#xD;
&#xD;
          5. Any pupil abnormalities (non-reactive, fixed, or abnormally shaped pupils);&#xD;
&#xD;
          6. Dilated pupil size of &lt; 6.0 mm;&#xD;
&#xD;
          7. Recurrent severe anterior or posterior segment inflammation or uveitis;&#xD;
&#xD;
          8. Subjects with conditions associated with increased risk of zonular rupture, including&#xD;
             capsular or zonular abnormalities that may lead to IOL decentration, including&#xD;
             pseudoexfoliation, trauma, or posterior capsule defects;&#xD;
&#xD;
          9. Known ocular or systemic disease that, in the opinion of the investigator, may affect&#xD;
             visual acuity or require surgical intervention during the course of the study,&#xD;
             [macular degeneration, cystoid macular edema, proliferative diabetic retinopathy&#xD;
             (severe), uncontrolled glaucoma, irregular corneal astigmatism, choroidal hemorrhage,&#xD;
             concomitant severe eye disease, extremely shallow anterior chamber, microphthalmos,&#xD;
             non-age related cataract, severe corneal dystrophy, severe optic nerve atrophy, etc.];&#xD;
&#xD;
         10. Use of systemic or ocular medications (e.g., Flomax) that may affect vision including&#xD;
             prior, current, or anticipated use during the course of the study that may, in the&#xD;
             opinion of the investigator, confound the outcome or increase the risk to the subject&#xD;
             (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract&#xD;
             surgery);&#xD;
&#xD;
         11. Patient is pregnant, plans to become pregnant, is lactating or has another condition&#xD;
             associated with the fluctuation of hormones that could lead to refractive changes;&#xD;
&#xD;
         12. Concurrent participation or participation within 30 days prior to the preoperative&#xD;
             visit in any other clinical study.&#xD;
&#xD;
         13. Planned monovision correction (eye designated for near correction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Surgical Vision Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Empire Eye and Laser Center, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Eye Clinic</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision, ND</name>
      <address>
        <city>W. Fargo</city>
        <state>North Dakota</state>
        <zip>58078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JW Eye Associates, P.A. DBA Key-Whitman Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Eye &amp; Laser Center, P.A.</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Devices Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

